SEC Form 4 · accession 0001209191-17-007053
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Mandell
Director
Period of report
Jan 31, 2017
Accepted (ET)
Feb 2, 2017 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 31, 2017 | M | 8,000 | $21.43 | A | 9,000 | D | |
| Common StockF2 | Jan 31, 2017 | S | 8,000 | $75.0402 | D | 1,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $21.43 | Jan 31, 2017 | M | 8,000 | A | — | Jan 8, 2024 | Common Stock | 8,000 | 4,000 | D |
Explanation of responses
- F1This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 13, 2016.
- F2The range in prices for the transaction reported on this line was $75.00 to $75.20. The average weighted price was $75.0402. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3This option vests ratably over three years in annual installments, commencing on January 8, 2014.